JP2023532415A - 改変セマフォリン3a、それを含む組成物およびその使用 - Google Patents

改変セマフォリン3a、それを含む組成物およびその使用 Download PDF

Info

Publication number
JP2023532415A
JP2023532415A JP2022574527A JP2022574527A JP2023532415A JP 2023532415 A JP2023532415 A JP 2023532415A JP 2022574527 A JP2022574527 A JP 2022574527A JP 2022574527 A JP2022574527 A JP 2022574527A JP 2023532415 A JP2023532415 A JP 2023532415A
Authority
JP
Japan
Prior art keywords
sema3a
modified
polypeptide
semaphorin
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022574527A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023532415A5 (cg-RX-API-DMAC7.html
Inventor
ザハバ バダッツ、
トービ、エリアス
ナスレン エイザ、
アディ サバグ、
ゲラ ニューフェルド、
オフラ ケスラー、
イー. イボンヌ ヨネス、
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medical Research & Development Fund for Health Services Bnai Zion Medical Center
Original Assignee
Medical Research & Development Fund for Health Services Bnai Zion Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medical Research & Development Fund for Health Services Bnai Zion Medical Center filed Critical Medical Research & Development Fund for Health Services Bnai Zion Medical Center
Publication of JP2023532415A publication Critical patent/JP2023532415A/ja
Publication of JP2023532415A5 publication Critical patent/JP2023532415A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
JP2022574527A 2020-06-04 2021-06-03 改変セマフォリン3a、それを含む組成物およびその使用 Pending JP2023532415A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063034476P 2020-06-04 2020-06-04
US63/034,476 2020-06-04
PCT/IL2021/050660 WO2021245670A1 (en) 2020-06-04 2021-06-03 Modified semaphorin 3a, compositions comprising the same and uses thereof

Publications (2)

Publication Number Publication Date
JP2023532415A true JP2023532415A (ja) 2023-07-28
JP2023532415A5 JP2023532415A5 (cg-RX-API-DMAC7.html) 2024-04-09

Family

ID=78830160

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022574527A Pending JP2023532415A (ja) 2020-06-04 2021-06-03 改変セマフォリン3a、それを含む組成物およびその使用

Country Status (8)

Country Link
US (1) US20230272020A1 (cg-RX-API-DMAC7.html)
EP (1) EP4161659A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023532415A (cg-RX-API-DMAC7.html)
CN (1) CN115916351A (cg-RX-API-DMAC7.html)
AU (1) AU2021284697A1 (cg-RX-API-DMAC7.html)
CA (1) CA3185618A1 (cg-RX-API-DMAC7.html)
IL (1) IL298678A (cg-RX-API-DMAC7.html)
WO (1) WO2021245670A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115947817B (zh) * 2023-02-22 2024-07-02 甘肃中肽生物科技有限公司 一种肿瘤相关多肽及其制备方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160129079A1 (en) * 2013-06-13 2016-05-12 Medical Research & Development Fund for Health Ser vices Bnai Zion Medical Center Semaphorin 3a for treatment and prognosis of systemic lupus erythematosus
JP2018506994A (ja) * 2015-02-23 2018-03-15 シーガル セラピューティクス エスアーエス 非天然セマフォリン3およびそれらの医学的使用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5288931A (en) * 1991-12-06 1994-02-22 Genentech, Inc. Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation
GB9912350D0 (en) * 1999-05-26 1999-07-28 European Molecular Biology Lab Embl Modified cytokine
FI117667B (fi) * 2001-07-05 2007-01-15 Univ Zuerich Farmaseuttinen koostumus, joka soveltuu käytettäväksi ortopediassa ja hammaslääketieteessä
EP2497498A4 (en) * 2009-11-05 2013-04-17 Univ Osaka THERAPEUTIC ACTIVE FOR AUTOIMMUNE DISEASES OR ALLERGIES AND METHOD FOR SCREENING AFTER THE THERAPEUTIC ACTIVE SUBSTANCE
WO2012106615A1 (en) * 2011-02-03 2012-08-09 Xoma Technology Ltd. Methods and materials for enhancing functional protein expression in bacteria
AU2015311563B2 (en) * 2014-09-05 2019-11-28 Rsem, Limited Partnership Compositions and methods for treating and preventing inflammation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160129079A1 (en) * 2013-06-13 2016-05-12 Medical Research & Development Fund for Health Ser vices Bnai Zion Medical Center Semaphorin 3a for treatment and prognosis of systemic lupus erythematosus
US10105413B2 (en) * 2013-06-13 2018-10-23 Medical Research & Development Fund for Health Services Bnai Zion Medical Center Semaphorin 3A for treatment of systemic lupus erythematosus
JP2018506994A (ja) * 2015-02-23 2018-03-15 シーガル セラピューティクス エスアーエス 非天然セマフォリン3およびそれらの医学的使用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GENOME BIOLOGY, vol. 7:211, JPN6025022116, 2006, ISSN: 0005609078 *
J. MOL. BIOL., vol. 425(22), JPN6025022118, 2013, pages 4405 - 4414, ISSN: 0005609077 *

Also Published As

Publication number Publication date
EP4161659A4 (en) 2024-03-06
IL298678A (en) 2023-01-01
WO2021245670A1 (en) 2021-12-09
EP4161659A1 (en) 2023-04-12
CN115916351A (zh) 2023-04-04
US20230272020A1 (en) 2023-08-31
CA3185618A1 (en) 2021-12-09
AU2021284697A1 (en) 2023-01-19

Similar Documents

Publication Publication Date Title
CN108004259B (zh) 靶向b细胞成熟抗原的嵌合抗原受体及其用途
KR20180131545A (ko) 트랜스포존 시스템 및 사용 방법
WO2020245343A1 (en) Chimeric autoantibody receptor (caar) that binds autoantibodies targeting the central nervous system in neurological autoimmune disease
KR101985271B1 (ko) Trail 및 cd를 발현하는 중간엽줄기세포 및 이의 용도
EP4310188A1 (en) Gene coding for chimeric receptor for anti-acetylcholine receptor autoantibody
KR20210043623A (ko) Hla-dr에 결합하는 키메라 항원 수용체 및 car-t 세포
JP2026035742A (ja) 生体高分子標的特異的補体阻害剤及びその製造方法と応用
EP3570852A1 (en) Methods of treating multiple sclerosis using autologous t cells
KR20220044683A (ko) 관절염 치료를 위한 hla-dr/cii 펩티드 복합체
KR20240099281A (ko) 항-steap2 키메라 항원 수용체 및 이의 용도
CN117083384A (zh) 工程细胞的基因转移载体和方法
CN113195528A (zh) 对ha-1h特异的结合蛋白及其用途
WO2024050551A2 (en) Compositions and methods for in vivo expression of chimeric antigen receptors
CN102030822A (zh) 人类新细胞因子VSTM1-v2及其应用
CN111378046B (zh) 一种免疫效应细胞转换受体
US20230272020A1 (en) Modified semaphorin 3a, compositions comprising the same and uses thereof
US20260042815A1 (en) Universal t cells and compositions and methods of use thereof
KR20220057596A (ko) 동종이계 세포 조성물 및 사용 방법
CN114702596B (zh) 靶向人cd33和nkg2dl的嵌合抗原受体细胞及其制备方法和应用
CN118221829A (zh) 一种il-10单体融合蛋白
AU2021219886A1 (en) Optimization of chimeric antigen receptor
CN115867584A (zh) 用于减少嵌合抗原受体强直信号传导的方法和组合物
JP2020180136A (ja) メラノーマの処置のための方法および組成物
EP4538285A1 (en) Pd-1 variant and use thereof
HK40103877A (en) Gene coding for chimeric receptor for anti-acetylcholine receptor autoantibody

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230705

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240327

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240327

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240416

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250603

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20251202